CohBar, Inc. to Announce 2018 Second Quarter Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
75
CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018

MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its second quarter 2018 financial results on Tuesday, August 14, 2018 and will host a conference call and provide a company update for shareholders at 2:00 p.m. Pacific Time on the same day.

Details for the Conference Call:

Date: August 14, 2018 Time: 2:00 p.m. (Pacific Time)

Conference Audio

  • Dial-in U.S. and Canada: (800) 239-9838
  • Dial-in International: (323) 794-2551
  • Conference ID No.: 9205786

For individuals participating in the Investor Call, we kindly request that you call into the conference audio approximately 10 minutes before the start time so that we can begin promptly.

An audio replay of the call will be available beginning at 5:00 p.m. Pacific Time on August 14, 2018, through 9:00 p.m. Pacific Time on September 4, 2018. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 9205786. The audio replay will also be available at www.cohbar.com from August 14, through September 4, 2018.

About CB4211

CB4211 is a first-in-class mitochondria based therapeutic that has demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial-derived peptide (MDP), which was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic collaborators and has been shown to play a significant role in the regulation of metabolism. Data were presented at the 2018 American Diabetes Association meeting providing in vitro evidence that CB4211 inhibits adipocyte lipolysis, a process that is foundational in the development of liver steatosis, through an insulin-dependent mechanism. These data provide a potential mechanistic explanation for previous observations in vivo, including efficacy of CB4211 in animal models of NASH, and anti-steatotic effects on livers of mice on a high fat diet, where a corresponding reduction in circulating fat and biomarkers of liver damage was also observed.  The activity of CB4211 appears to be specific to sensitizing insulin action on the insulin receptor. NASH has been estimated to affect as many as 12% of adults in the U.S. and there is currently no approved treatment for the disease.

About CohBar

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company information, please visit  www.cohbar.com .

Forward-Looking Statements

This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include CohBar’s plans and expectations for its lead CB4211 drug candidate program, including statements regarding the efficacy, mechanism of action and therapeutic and commercial potential of CB4211 and other mitochondria based therapeutics. Forward-looking statements are based on current expectations, projections and interpretations that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These include uncertainties inherent in research and development, such as the possible inability to complete clinical studies as anticipated, the possibility of unfavorable study results, including unfavorable new data or additional analyses of existing data; risks associated with initial data, including the risk that results of clinical studies may be different from (including less favorable than) those suggested by earlier data results and may not support further clinical development or which otherwise affect the viability or commercial potential of CB4211 or other candidate programs.  Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov  or  www.sedar.com .

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable laws. 

Investor and Media Contact: Jeff Biunno, CFO CohBar, Inc. (650) 446-7888, Option 3 jeff.biunno@cohbar.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 13

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 67

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 136

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 78

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 63

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 58

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 59

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 80

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Technology Acquisition Corp. I Initiates Liquidation Process

Updated Category News Views 212

Global Technology Acquisition Corp. I Announces Dissolution of Operations Global Technology Acquisition Corp. I (Nasdaq: GTAC) finds itself at a pivotal moment, as the company has declared its intent to dissolve and liquidate its operations. This decision arises from the inability to complete an initial business combination within the mandated timeframe outlined in its...

Continue Reading
Empowering Leadership Development: McLean & Company Insights

Updated Category News Views 483

Leadership Development: Key to Organizational Success In today's fast-evolving work landscape, the significance of leadership development has never been clearer. Global HR research firm McLean & Company emphasizes that cultivating effective leaders at every level is crucial for organizational success. Their comprehensive research highlights a four-step process that...

Continue Reading
Investigation Launched into Aviat Networks, Inc. Securities Fraud

Updated Category News Views 144

Investigation into Aviat Networks, Inc. Recent developments regarding Aviat Networks, Inc. have raised significant concerns among investors about their financial future. The company is now under scrutiny from legal experts due to possible allegations of securities fraud. The Portnoy Law Firm is actively investigating these issues and has begun reaching out to investors...

Continue Reading
GR Silver Mining Plans $1.76 Million Private Placement Funding

Updated Category News Views 99

GR Silver Mining Ltd.'s Strategic Private Placement GR Silver Mining Ltd. (GRSL, GRSLF) has announced a plan to raise up to $1.76 million through a non-brokered private placement. This strategic initiative is designed to boost exploration efforts, particularly focusing on expanding resources at the San Marcial Area within the Plomosas Project. Details of the Offering The...

Continue Reading
BRT Apartments Corp. Declares Exciting New Dividend

Updated Category News Views 121

BRT Apartments Corp. announces a quarterly dividend BRT Apartments Corp. has declared a quarterly dividend of $0.25 per share. Approved by the Board of Directors, this action continues the company’s practice of returning cash to shareholders as part of its ongoing financial plan. It’s a straightforward move that underscores a focus on steady, shareholder-minded...

Continue Reading